10-Q: PetVivo Holdings Reports Strong Revenue Growth, Secures Capital
Quarterly Report
PetVivo Holdings, Inc. announced a significant increase in revenue for the quarter ended June 30, 2025, driven by new product sales, while also securing $5 million in Series B preferred stock funding to bolster liquidity.
Summary
- Total revenues for the three months ended June 30, 2025, increased by 140.4% to $297,500, up from $123,751 in the prior year period.
- Sales of Spryng products contributed $148,243, and the newly licensed Precise PRP products generated $149,257 in revenue.
- Operating loss improved by 9.8% to $(1,844,317) for the quarter, compared to $(2,044,432) in the same period last year.
- Net loss for the quarter increased to $(2,311,037) from $(2,047,063) year-over-year, primarily due to non-operating items like unrealized loss on derivative liabilities and loss on asset disposal.
- Net loss per share improved to $(0.09) from $(0.11) due to an increase in weighted average common shares outstanding.
- Cash and cash equivalents significantly increased to $3,303,844 at June 30, 2025, from $227,689 at March 31, 2025, largely due to financing activities.
- The company received $4,400,000 from the Series B preferred stock subscription receivable during the quarter, contributing to $4,709,910 in net cash provided by financing activities.
- Working capital stood at $1,283,426 as of June 30, 2025.
- Material weaknesses in internal control over financial reporting were identified, related to accounting for convertible notes, beneficial conversion features, warrant debt discounts, and derivative liabilities, with remediation efforts underway.
Sentiment
Score: 6
Explanation: The company demonstrated strong revenue growth and significantly improved its liquidity through a capital raise, addressing immediate 'going concern' risks. However, it continues to incur net losses and faces internal control weaknesses, indicating ongoing challenges despite positive operational momentum.
Positives
- Total revenues increased by 140.4% to $297,500 for the quarter, demonstrating strong top-line growth.
- The introduction of Precise PRP products through an exclusive licensing agreement generated $149,257 in new revenue, diversifying the product portfolio.
- Operating loss decreased by 9.8% to $(1,844,317), indicating improved operational efficiency.
- General and administrative expenses decreased by 13.3% and research and development expenses decreased by 12.1%, reflecting cost-cutting initiatives.
- Cash and cash equivalents increased substantially to $3,303,844, significantly improving the company's liquidity position.
- The company successfully raised $5,000,000 through the sale of Series B convertible preferred stock, providing capital for operations until December 31, 2025.
- Series A Preferred Stock was converted to Common Stock on July 18, 2025, simplifying the capital structure.
- Plans are in place for a second ISO cleanroom facility to enhance production capacity and minimize supply risks.
Negatives
- Net loss increased by 12.9% to $(2,311,037) for the quarter, primarily due to non-operating items.
- Cost of sales increased significantly by 752.5% to $110,774, outpacing revenue growth.
- The company continues to incur net cash used in operating activities, totaling $(1,633,755) for the quarter.
- A 'going concern' warning remains due to continued operating losses and the ongoing need for additional financing.
- Material weaknesses in internal control over financial reporting were identified, requiring significant remediation efforts.
- Distribution agreements with MWI Veterinary Supply Co. and Covetrus North America LLC were mutually terminated in March and February 2025, respectively.
Risks
- Substantial doubt exists about the company's ability to continue as a going concern due to continued operating losses and the need for additional financing.
- Material weaknesses in internal control over financial reporting, specifically concerning the accounting for modifications of convertible notes, measurement of beneficial conversion features, warrant debt discounts, and derivative liabilities, could impact financial reporting reliability.
- The company's ability to raise additional capital in the future is subject to various factors, including overall business performance and market conditions, with no guarantee of success.
- Reliance on new distribution partnerships (Vedco, Clipper) for product sales introduces dependency and potential market penetration challenges.
- The company operates in a competitive animal health market, with existing treatments for osteoarthritis that may limit market adoption of Spryng.
- Future pipeline products may be subject to regulatory approval by agencies like the FDA or CVM, which can be a lengthy and costly process.
- Uncertainty regarding the full impact of the recently enacted Taxpayer Fairness and Growth Act of 2025 on deferred tax assets and liabilities.
Future Outlook
The company expects revenues from the VetStem Precise PRP product in fiscal year 2026 and plans to increase commercialization efforts for Spryng in the United States through sales representatives, clinical studies, and market awareness. A second ISO cleanroom facility is anticipated to be operational later this year to minimize supply risks and scale production. The product pipeline is expected to grow through acquisitions or in-licensing, and strategic out-licensing partnerships may be established for secondary revenues. Proceeds from the Series B preferred stock offering are believed to be sufficient to fund operations until December 31, 2025. Remediation of material weaknesses in internal control over financial reporting is expected to be completed by the end of fiscal year March 31, 2026. The recently enacted Taxpayer Fairness and Growth Act of 2025 is expected to have a favorable impact on the effective tax rate starting in fiscal 2027.
Management Comments
- Management believes that the actions presently being taken to further implement its business plan will enable the Company to continue as a going concern.
- Management is in the process of implementing measures designed to ensure that the control deficiencies contributing to the material weaknesses are remediated, such that these controls are designed, implemented, and operating effectively.
- We believe that these actions will remediate the material weaknesses with our internal control over financial reporting.
Industry Context
PetVivo Holdings operates in the $11 billion companion animal veterinary care and product sales market, specifically targeting osteoarthritis in dogs and horses, which affects approximately 14 million dogs and 1 million horses. The company positions its Spryng product as an alternative to traditional treatments like NSAIDs, steroids, and hyaluronic acid injections, which often have side effects or are short-lasting. With veterinary practices seeking to replace lost prescription revenues due to online pharmacies, Spryng, as a veterinarian-administered medical device, aims to expand practice revenues and margins, potentially accelerating its adoption as a standard of care.
Comparison to Industry Standards
- Spryng offers a biocompatible lubricious cushion to the joint, providing an alternative to NSAIDs which are approved to alleviate pain and inflammation but carry risks of gastrointestinal, kidney, and liver damage.
- Unlike steroid and/or hyaluronic acid injections that can be slow-acting or short-lasting, case studies indicate Spryng-treated animals show long-lasting multi-month improvement in lameness.
- A single injection of Spryng is approximately $600 to $900 per joint and typically lasts for at least 12 months, positioning it as an effective and economical solution compared to other treatments.
- The company aims for Spryng to become the standard of care for canine and equine lameness related to synovial joint issues, addressing a gap where veterinary clinics have few effective treatments.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Control Weaknesses | Identified material weaknesses in the design and operation of controls over the accounting for modifications of convertible notes, measurement of beneficial conversion features, warrant debt discounts, and derivative liabilities. | 2025-06-30 | Requires significant remediation efforts to ensure reliability of financial reporting; management plans to tighten ICFR controls, improve training, and hire additional accounting personnel. |
Legal Proceedings
- The company may become involved in legal proceedings arising in the ordinary course of business, but does not anticipate them having a material adverse effect on its business, financial condition, or results of operations.
Stakeholder Impact
- Shareholders: Experience dilution from common stock issuances for services, warrant exercises, and RSU vesting, but benefit from improved liquidity and potential for future growth from new products and market expansion.
- Employees: Receive stock-based compensation and performance bonuses, and participate in a 401(k) retirement plan.
- Customers (Veterinarians): Gain access to new products like Precise PRP and an alternative treatment (Spryng) for osteoarthritis, potentially increasing their practice revenues and margins.
- Creditors: Hold various promissory and convertible notes, with some maturity dates extended and conversion features amended.
Next Steps
- Increase commercialization efforts for Spryng in the United States through sales representatives, clinical studies, and market awareness.
- Operationalize a second ISO cleanroom facility later this year to minimize supply risks and scale production capacity.
- Grow the product pipeline through the acquisition or in-licensing of additional proprietary products.
- Establish strategic out-licensing partnerships to generate secondary revenues.
- Remediate material weaknesses in internal control over financial reporting, with expected completion prior to the end of fiscal year March 31, 2026.
- Evaluate the impact of the Taxpayer Fairness and Growth Act of 2025 on consolidated financial statements, including deferred tax assets and liabilities.
Key Dates
| Date | Description |
|---|---|
| 2009 | PetVivo Holdings, Inc. incorporated in Nevada under its former name. |
| 2014 | Entered current business through a stock exchange reverse merger with PetVivo, Inc. |
| 2017-04 | Acquired Gel-Del Technologies, Inc. through a statutory merger. |
| 2017-05 | Entered into an 84-month lease for office, laboratory, and warehouse space in Edina, Minnesota. |
| 2020-01 | Entered into a lease amendment for corporate office facility, extending term through November 2026. |
| 2020-07-10 | Board of Directors approved the PetVivo Holdings, Inc. 2020 Equity Incentive Plan. |
| 2020-09-22 | Stockholders approved the 2020 Equity Incentive Plan. |
| 2020-11-05 | Entered into a clinical trial services agreement with Colorado State University. |
| 2021-02 | Established a 401(k)-retirement plan for employees. |
| 2021-09 | Began commercialization of Spryng with OsteoCushion Technology. |
| 2022-01 | Entered into a 63-month lease for office space in Edina, Minnesota, expiring March 2027. |
| 2022-03 | Successfully completed an equine tolerance study. |
| 2022-05 | Began first canine clinical study with Ethos Veterinary Health. |
| 2022-06-17 | Entered into a Distribution Services Agreement with MWI Veterinary Supply Co. |
| 2022-10-14 | Stockholders approved the Amended and Restated 2020 Equity Incentive Plan. |
| 2023-01-10 | Entered into a new lease agreement for production and warehouse space. |
| 2023-04-01 | Commencement date for the new production and warehouse space lease. |
| 2023-06 | Began second canine clinical study with Ethos Veterinary Health. |
| 2023-10 | Anticipated completion of the first canine clinical study with Ethos Veterinary Health. |
| 2023-12-18 | Entered into a Distribution Services Agreement with Covetrus North America LLC. |
| 2024-03 | Expected completion of university clinical study with Colorado State University. |
| 2024-09-09 | Entered into a convertible promissory note for $150,000. |
| 2024-09-27 | Entered into a convertible promissory note for $350,000. |
| 2024-10-10 | Began entering into additional convertible promissory notes totaling $650,000 through December 30, 2024. |
| 2024-10 | Expected completion of the second canine clinical study with Ethos Veterinary Health. |
| 2024-12 | Entered into new distribution partnerships with Vedco, Inc. and Clipper Distributing, LLC. |
| 2024-12-20 | Entered into a promissory note for $100,000 and a convertible promissory note for $25,000. |
| 2025-02 | Signed an exclusive licensing agreement with VetStem, Inc. to market and sell Precise PRP products. |
| 2025-02 | Mutually terminated non-exclusive distribution agreement with Covetrus. |
| 2025-02-12 | Began entering into additional convertible promissory notes totaling $540,000 through March 13, 2025. |
| 2025-02-14 | Issued 250,000 warrants for two notes totaling $500,000. |
| 2025-03 | Mutually terminated non-exclusive distribution agreement with MWI. |
| 2025-03-03 | Entered into a promissory note for an additional $200,000. |
| 2025-03-26 | Entered into a Subscription Agreement to receive $5,000,000 shares of Series B Preferred Stock. |
| 2025-04 | Changed the name of wholly-owned subsidiary PetVivo, Inc. to PetVivo Animal Health, Inc. |
| 2025-04 | Issued 20,000 shares to service providers for consulting services. |
| 2025-04 | Issued 52,500 shares of common stock upon vesting of restricted stock units to board members. |
| 2025-05 | Issued 20,000 shares to service providers for consulting services. |
| 2025-05 | Entered into three separate promissory notes totaling $12,000 through June 2025. |
| 2025-06 | Issued 8,000 shares to a consultant for conversion of accounts payable. |
| 2025-06 | Issued 70,000 shares of common stock for warrant exercise. |
| 2025-06 | Issued 30,157 shares of common stock upon vesting of restricted stock units to employees. |
| 2025-06-10 | Entered into an additional convertible promissory note for $160,000. |
| 2025-06-24 | Received and funded the remaining $4,400,000 for Series B Preferred Stock. |
| 2025-06-30 | End of the quarterly reporting period. |
| 2025-06-30 | Terminated ten-year lease agreement on production and warehouse space. |
| 2025-06-30 | Amendment to convertible notes to fix conversion price at $0.50 per share and eliminate variable pricing feature. |
| 2025-07-01 | Issued 52,500 shares related to vesting of restricted stock units. |
| 2025-07-01 | Issued 16,694 shares of restricted common stock to an employee. |
| 2025-07-01 | Issued 19,372 shares of restricted common stock to a board member for consulting compensation. |
| 2025-07-02 | Congress enacted the Taxpayer Fairness and Growth Act of 2025. |
| 2025-07-14 | Paid back three promissory notes totaling $12,000 plus accrued interest. |
| 2025-07-15 | Paid back promissory notes totaling $300,000 plus accrued interest. |
| 2025-07-18 | Converted 3,045,000 shares of Series A Preferred Stock to Common Stock. |
| 2025-07-29 | Issued 367,850 shares of restricted common stock to four employees for performance bonuses. |
| 2025-08-14 | Date of filing of the 10-Q report and shares outstanding date. |
| 2025-09-03 | Maturity date for $200,000 promissory note from March 3, 2025. |
| 2025-09-30 | Amended maturity date for convertible notes totaling $540,000 from February-March 2025. |
| 2025-12-31 | Expected period for which Series B preferred stock proceeds are sufficient to fund operations. |
| 2025-12-31 | Amended maturity date for several convertible and non-convertible promissory notes. |
| 2026-01-01 | Effective date for federal corporate income tax rate reduction to 19%. |
| 2026-03-31 | Expected completion of remediation for material weaknesses in internal control over financial reporting. |
| 2026-11 | Extended lease term for corporate office facility. |
| 2027-03 | Lease expiration for office space entered in January 2022. |
| 2027-03-31 | Expected start of favorable impact on effective tax rate from new federal tax legislation. |
| 2030-07-10 | Termination date for the Amended and Restated 2020 Equity Incentive Plan. |
| 2033-06-30 | Termination date for the production and warehouse space lease entered in January 2023. |
Recommendation
holdPetVivo Holdings has demonstrated promising revenue growth, particularly with the introduction of a new product, and has significantly strengthened its short-term liquidity through a substantial capital raise. This addresses immediate 'going concern' risks and provides a runway for continued operations and commercialization efforts. However, the company continues to operate at a net loss, faces challenges with internal control weaknesses, and will require further capital raises in the future. While the operational improvements and cash infusion are positive, the long-term profitability and sustained market adoption of its products remain uncertain, warranting a 'hold' position for investors to observe further execution and remediation progress.
Keywords
PetVivo Holdings, PETV, 10-Q, Quarterly Report, Animal Health, Spryng, OsteoCushion Technology, Precise PRP, VetStem, Veterinary Medical Device, Osteoarthritis, Financial Results, Revenue Growth, Net Loss, Liquidity, Capital Raise, Convertible Notes, Internal Controls, Going Concern, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.